Iteos Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Iteos Therapeutics
ITOS Stock  USD 10.17  0.02  0.20%   
Iteos Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Iteos Therapeutics' valuation are provided below:
Gross Profit
35 M
Market Capitalization
449.2 M
Enterprise Value Revenue
1.2621
Revenue
35 M
Earnings Share
(3.05)
There are over one hundred nineteen available fundamental trends for Iteos Therapeutics, which can be analyzed over time and compared to other ratios. All traders should confirm Iteos Therapeutics' regular fundamentals against the performance from 2010 to 2025 and make sure the trends continue to evolve in the right direction. Market Cap is likely to drop to about 265.8 M in 2025. Enterprise Value is likely to drop to about 189.9 M in 2025

Iteos Therapeutics Total Revenue

33.25 Million

Check Iteos Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Iteos Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 17.6 M, Net Interest Income of 32.4 M or Interest Income of 16.1 M, as well as many indicators such as Price To Sales Ratio of 9.46, Dividend Yield of 0.0 or PTB Ratio of 0.5. Iteos financial statements analysis is a perfect complement when working with Iteos Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Iteos Stock
Check out the analysis of Iteos Therapeutics Correlation against competitors.
For more information on how to buy Iteos Stock please use our How to Invest in Iteos Therapeutics guide.

Iteos Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets533.8 M687 M259.4 M
Slightly volatile
Short and Long Term Debt Total4.4 M5.1 M5.8 M
Slightly volatile
Other Current Liabilities18.7 M27.2 M10.2 M
Slightly volatile
Total Current Liabilities72.2 M40.4 M35.8 M
Slightly volatile
Total Stockholder Equity429.9 M590.3 M205.4 M
Slightly volatile
Other Liabilities55.3 M52.7 M18.6 M
Slightly volatile
Property Plant And Equipment Net6.1 M10 M3.4 M
Slightly volatile
Current Deferred Revenue1.3 M1.4 M19.4 M
Pretty Stable
Accounts Payable6 M8.5 M3.4 M
Slightly volatile
Cash135 M142.1 M138.5 M
Slightly volatile
Non Current Assets Total186.3 M177.4 M41.3 M
Slightly volatile
Non Currrent Assets Other4.1 M7.1 M3.1 M
Slightly volatile
Other Assets2.2 M1.5 M2.5 M
Slightly volatile
Cash And Short Term Investments450.4 M494.6 M218.3 M
Slightly volatile
Net Receivables5 M3.7 M2.9 M
Slightly volatile
Common Stock Total Equity31 K32.4 K61.8 K
Slightly volatile
Common Stock Shares Outstanding32.1 M40.5 M18.5 M
Slightly volatile
Liabilities And Stockholders Equity533.8 M687 M259.4 M
Slightly volatile
Non Current Liabilities Total31.7 M56.3 M18.2 M
Slightly volatile
Capital Surpluse342.5 M501 M182.6 M
Slightly volatile
Other Current Assets8.6 M11.2 M4.2 M
Slightly volatile
Total Liabilities103.9 M96.7 M54 M
Slightly volatile
Total Current Assets464 M509.5 M225.4 M
Slightly volatile
Capital Stock35.1 K37 K17.8 M
Slightly volatile
Non Current Liabilities Other60 M57.1 M15.6 M
Slightly volatile
Net Working Capital391.7 M469.2 M189.6 M
Slightly volatile
Short Term Debt1.6 M1.3 M1.9 M
Pretty Stable
Common Stock30.5 K37 K62.1 K
Slightly volatile
Property Plant Equipment1.8 M2.4 M1.5 M
Slightly volatile
Property Plant And Equipment Gross10.2 M14.9 M6 M
Slightly volatile

Iteos Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Income16.1 M30.9 M5.6 M
Slightly volatile
Depreciation And Amortization819.5 K1.2 M629.7 K
Slightly volatile
Selling General Administrative33.4 M49.1 M17.5 M
Slightly volatile
Other Operating Expenses104.7 M194.5 M57.1 M
Slightly volatile
Research Development75.7 M145.4 M43.4 M
Slightly volatile
Cost Of Revenue819.5 K1.2 M629.7 K
Slightly volatile
Total Operating Expenses104.7 M194.5 M57.1 M
Slightly volatile
Reconciled Depreciation815.4 K1.2 M627.8 K
Slightly volatile
Total Other Income Expense Net20.7 M39.2 M11.2 M
Slightly volatile
Preferred Stock And Other Adjustments199.2 K224.1 K244.3 K
Slightly volatile

Iteos Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation15.3 M29.9 M7.1 M
Slightly volatile
Begin Period Cash Flow280.1 M251.5 M138.3 M
Slightly volatile
Other Cashflows From Financing Activities2.1 M2.2 M23.2 M
Pretty Stable
Depreciation816 K1.2 M628.1 K
Slightly volatile
Capital Expenditures1.3 M1.6 M693.1 K
Slightly volatile
Total Cash From Financing Activities128.4 M122.2 M52 M
Slightly volatile
End Period Cash Flow135.3 M142.4 M138.6 M
Slightly volatile
Net Borrowings1.6 M953.1 K3.1 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio9.468.88126.8151
Slightly volatile
PTB Ratio0.50.52668.5943
Slightly volatile
Days Sales Outstanding48.638.491927.0232
Slightly volatile
Book Value Per Share8.7714.58446.3449
Slightly volatile
Stock Based Compensation To Revenue0.620.85550.2613
Slightly volatile
Capex To Depreciation1.141.31910.9226
Slightly volatile
PB Ratio0.50.52668.5943
Slightly volatile
EV To Sales4.094.9663.1187
Slightly volatile
Payables Turnover0.240.14560.2945
Slightly volatile
Sales General And Administrative To Revenue1.141.40230.5073
Slightly volatile
Research And Ddevelopement To Revenue2.744.15561.1451
Slightly volatile
Capex To Revenue0.05780.04670.024
Slightly volatile
Cash Per Share9.3212.22137.1433
Slightly volatile
Days Payables Outstanding2 K2.5 K1.7 K
Slightly volatile
Current Ratio8.4112.62497.4836
Slightly volatile
Tangible Book Value Per Share8.7714.58446.3449
Slightly volatile
Receivables Turnover9.019.482529.5343
Very volatile
Shareholders Equity Per Share8.7714.58446.3449
Slightly volatile
Debt To Equity0.00820.00860.2613
Slightly volatile
Capex Per Share0.02790.04030.032
Pretty Stable
Graham Net Net7.149.90095.052
Slightly volatile
Revenue Per Share0.820.86477.9477
Slightly volatile
Interest Debt Per Share0.120.12590.5414
Slightly volatile
Debt To Assets0.0070.00740.1435
Slightly volatile
Graham Number44.1238.8544.2315
Slightly volatile
Price Book Value Ratio0.50.52668.5943
Slightly volatile
Days Of Payables Outstanding2 K2.5 K1.7 K
Slightly volatile
Ebt Per Ebit0.970.75440.8664
Pretty Stable
Company Equity Multiplier1.561.16381.6267
Slightly volatile
Total Debt To Capitalization0.00810.00860.1858
Slightly volatile
Debt Equity Ratio0.00820.00860.2613
Slightly volatile
Quick Ratio8.4212.62497.4877
Slightly volatile
Net Income Per E B T0.761.11690.9629
Slightly volatile
Cash Ratio3.353.52165.3824
Pretty Stable
Days Of Sales Outstanding48.638.491927.0232
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.821.01661.0014
Slightly volatile
Price To Book Ratio0.50.52668.5943
Slightly volatile
Fixed Asset Turnover3.333.505637.9089
Slightly volatile
Debt Ratio0.0070.00740.1435
Slightly volatile
Price Sales Ratio9.468.88126.8151
Slightly volatile
Asset Turnover0.04840.05090.3218
Slightly volatile
Gross Profit Margin1.070.96460.9962
Very volatile
Price Fair Value0.50.52668.5943
Slightly volatile

Iteos Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap265.8 M279.8 M395.6 M
Slightly volatile
Enterprise Value189.9 M199.9 M276.3 M
Slightly volatile

Iteos Fundamental Market Drivers

Forward Price Earnings12.5628
Cash And Short Term Investments494.6 M

Iteos Upcoming Events

20th of March 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
20th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Iteos Therapeutics Financial Statements

Iteos Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Iteos Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Iteos Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Iteos Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue1.4 M1.3 M
Total Revenue35 M33.2 M
Cost Of Revenue1.2 M819.5 K
Stock Based Compensation To Revenue 0.86  0.62 
Sales General And Administrative To Revenue 1.40  1.14 
Research And Ddevelopement To Revenue 4.16  2.74 
Capex To Revenue 0.05  0.06 
Revenue Per Share 0.86  0.82 
Ebit Per Revenue(4.56)(4.79)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Iteos Stock Analysis

When running Iteos Therapeutics' price analysis, check to measure Iteos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Iteos Therapeutics is operating at the current time. Most of Iteos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Iteos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Iteos Therapeutics' price. Additionally, you may evaluate how the addition of Iteos Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY